Although the findings support a potential direct antifibrotic effect of Aramchol in NASH patients, further investigation is needed to understand the additional mechanisms besides SCD1 inhibition by which Aramchol exerts its antifibrotic effects in patients. The gene discussed is SCD; the disease is metabolic dysfunction-associated steatohepatitis.